This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Encompass Health (EHC) Opens New 50-Bed Hospital in Naples
by Zacks Equity Research
With the new facility in Naples, Encompass Health (EHC) now has 153 inpatient rehabilitation units in total.
HCA Healthcare (HCA) Invests in VitalConnect's Remote Monitoring
by Zacks Equity Research
HCA Healthcare's (HCA) investment is likely to advance technology in the medical space, helping patients as well as professionals.
Is Aerie Pharmaceuticals (AERI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aerie Pharmaceuticals (AERI) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Is Alignment Healthcare (ALHC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alignment Healthcare (ALHC) and Hanger (HNGR) have performed compared to their sector so far this year.
Wall Street Analysts See a 33% Upside in Alignment Healthcare (ALHC): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 32.9% upside potential for Alignment Healthcare (ALHC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has Alignment Healthcare (ALHC) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alignment Healthcare (ALHC) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Alignment Healthcare (ALHC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 76.92% and 8.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alignment Healthcare (ALHC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 4.17% and 3.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Alignment Healthcare (ALHC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Alignment Healthcare (ALHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.